Close Menu

NEW YORK (GenomeWeb) – Next year, precision medicine company Ignyta will submit two applications for its lead therapeutic product entrectinib — one in ROS1-positive non-small cell lung cancer, and another for patients with any kind of solid tumor characterized by NTRK-fusions.

Ignyta not only plans to garner near concurrent review and approval entrectinib for the two indications, but also aims to introduce a multimarker NGS-based companion diagnostic on the market alongside the drug, which can identify patients who have these biomarkers and are most likely to respond.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Jul
23

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.